Drug
Cabozantinib clinical trials
Also written XL184, Cabometyx, Cometriq and BMS-907351.
- studies test it
- 199
- open now
- 35
- in phase 3
- 19
- first study started
- 2005
Keep track of what changes. Save the cabozantinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
199 studies that test it; most in 2020 (33)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 16 |
| 2013 | 18 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 10 |
| 2018 | 23 |
| 2019 | 15 |
| 2020 | 33 |
| 2021 | 18 |
| 2022 | 12 |
| 2023 | 13 |
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 51
- Phase 2
- 139
- Phase 3
- 19
- Phase 4
- 3
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 37 · Other 162
National Cancer Institute (NCI) (25) · Exelixis (22) · M.D. Anderson Cancer Center (13) · Dana-Farber Cancer Institute (7) · Memorial Sloan Kettering Cancer Center (6) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (5) · Massachusetts General Hospital (5) · Bristol-Myers Squibb (4)
Often tested with
Tested in the same studies.
Nivolumab (28) · Ipilimumab (15) · Pembrolizumab (13) · Atezolizumab (11) · Lenvatinib (9) · Erlotinib (6) · Sunitinib (6) · Temozolomide (5)
Studies
Open first, then newest update. How each study uses cabozantinib is read from its arms, and is right about nine times in ten.
Testing it · 199
- Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2University of Texas Southwestern Medical CenterNCT05931393Written as Cabozantinib 80 MG
- A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06835972Written as Cabozantinib
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07405164Written as Cabozantinib
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsRecruitingPhase 1Kura Oncology, Inc.NCT06026410Written as Cabozantinib
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT01639508Written as Cabozantinib
- Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to RelapseRecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT07871864Written as Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles
- Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT05019703Written as Cabozantinib
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingPhase 1Girish Dhall, MDNCT06502171Written as Cabozantinib Oral Tablet
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07194044Written as Cabozantinib
- Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT06475989Written as Cabozantinib
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Cabozantinib
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05048212Written as Cabozantinib
- Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasRecruitingPhase 1Children's Hospital of PhiladelphiaNCT06156410Written as Cabozantinib
- Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT05361720Written as Cabozantinib
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationPhase 3ExelixisNCT07620574Written as Cabozantinib
- Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1University of UtahNCT05613894Written as Cabozantinib
- Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyRecruitingPhase 1M.D. Anderson Cancer CenterNCT07187869Written as Cabozantinib
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingPhase 1M.D. Anderson Cancer CenterNCT05092373Written as Cabozantinib S-malate
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as Cabozantinib
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingPhase 2University of California, IrvineNCT04472767Written as Cabozantinib
See all 199 studies that test cabozantinib →
Given in every arm · 43 — cabozantinib is usual care beside what is tested
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingPhase 2National Cancer Institute (NCI)NCT05136196Written as Cabozantinib S-malate
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Cabozantinib
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingPhase 1/2Bristol-Myers SquibbNCT07293351Written as Cabozantinib
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382Written as Cabozantinib S-malate
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialRecruitingPhase 1/2National Cancer Institute (NCI)NCT06811116Written as Cabozantinib S-malate
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Written as Cabozantinib
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345Written as Cabozantinib
- A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)Not yet recruitingPhase 1Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07848295Written as Cabozantinib
- Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaRecruitingPhase 3Arcus Biosciences, Inc.NCT07011719Written as Cabozantinib
- Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06900595Written as Cabozantinib
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerRecruitingPhase 2Academic and Community Cancer Research UnitedNCT05168163Written as Cabozantinib
- Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsRecruitingPhase 2Fox Chase Cancer CenterNCT05263050Written as Cabozantinib
- Autologous Dendritic Cell Vaccine in Kidney CancerRecruitingPhase 2Jodi MaranchieNCT05127824Written as Cabozantinib
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT07383441Written as Cabozantinib
- Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CancerRecruitingPhase 1Emory UniversityNCT04878029Written as Cabozantinib S-malate
- Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical CancerRecruitingPhase 2Emory UniversityNCT06006013Written as Cabozantinib S-malate
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingPhase 1/2Anwaar SaeedNCT03539822Written as Cabozantinib
- A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular CarcinomaRecruitingPhase 1/2Iterion TherapeuticsNCT05797805Written as Cabozantinib
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as Cabozantinib
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as Cabozantinib
Showing 20 of 43.
As the comparator · 8 — what is tested is compared with cabozantinib
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05773274Written as Cabozantinib
- Cabozantinib Dose Skipping as an Alternative to Dose ReductionsRecruitingPhase 2dr. Tom van der HulleNCT07077161Written as Cabozantinib
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07227402Written as Cabozantinib
- Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05012371Written as Cabozantinib
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT04586231Written as Cabozantinib
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingPhase 3Loxo Oncology, Inc.NCT04211337Written as Cabozantinib
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnPhase 3Hoffmann-La RocheNCT04760288Written as Cabozantinib
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedPhase 3Nektar TherapeuticsNCT03729245Written as cabozantinib
Codes
What other systems call cabozantinib · ClinicalTrials.gg INT005839
- MeSH (NLM) C558660cabozantinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1C39JW444GCABOZANTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1363268Confirmed FDA, Wikidata
- Wikidata Q795057cabozantinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C52200CabozantinibOne source FDA
- DrugBank DB08875One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C558660 | cabozantinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1C39JW444G | CABOZANTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1363268 | — | Confirmed FDA, Wikidata |
| Wikidata | Q795057 | cabozantinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C52200 | Cabozantinib | One source FDA |
| DrugBank | DB08875 | — | One source Wikidata |
Also registered as cabozantinib s-malate (UNII DR7ST46X58 · RxNorm 1363267).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.